{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:03:35Z","timestamp":1781953415913,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/igc.0b013e31829f17c9","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T08:27:54Z","timestamp":1375345674000},"page":"1219-1225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Jose Alejandro","family":"Rauh-Hain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie H.","family":"Guseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine M.","family":"Esselen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitfield B.","family":"Growdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Schorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn N.","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela G.","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don S.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e31829f17c9_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","article-title":"Worldwide burden of gynaecological cancer: the size of the problem","volume":"20","author":"Sankaranarayanan","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0010","first-page":"277","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0015","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0030","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0b013e31823532ce","article-title":"Extraperitoneal metastases from recurrent ovarian cancer","volume":"22","author":"Robinson","year":"2012","journal-title":"IntJ Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0040","series-title":"WHO Handbook for Reporting Results of Cancer Treatments","year":"1979"},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0045","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/1097-0142(19850301)55:5<1129::AID-CNCR2820550531>3.0.CO;2-O","article-title":"Prognosis of surgically determined complete responders in advanced ovarian cancer","volume":"55","author":"Gershenson","year":"1985","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0090-8258(91)90333-Z","article-title":"Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy","volume":"42","author":"Rubin","year":"1991","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","article-title":"Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy","volume":"127","author":"Esselen","year":"2012","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0065","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2009.25.1082","article-title":"Increased incidence of visceral metastases in Scottish patients with BRCA1\/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype","volume":"28","author":"Gourley","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0070","doi-asserted-by":"crossref","first-page":"778","DOI":"10.6004\/jnccn.2009.0056","article-title":"NCCN Clinical Practice Guidelines in Oncology: colon cancer","volume":"7","author":"Engstrom","year":"2009","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0075","doi-asserted-by":"crossref","first-page":"v93","DOI":"10.1093\/annonc\/mdq222","article-title":"Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment","volume":"21","author":"Van Cutsem E, Nordlinger B, Cervantes A; ESMO Guidelines Working Group","year":"2010","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1091-255X(02)00121-X","article-title":"Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases","volume":"7","author":"Allen","year":"2003","journal-title":"J Gastrointest Surg."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0085","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0090","first-page":"395","article-title":"Emerging treatment options for management of malignant ascites in patients with ovarian cancer","volume":"4","author":"Eskander","year":"2012","journal-title":"Int J Womens Health."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0095","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","article-title":"Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?","volume":"14","author":"Kobold","year":"2009","journal-title":"Oncologist."},{"key":"10.1097\/IGC.0b013e31829f17c9_bb0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24019534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24019534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e31829f17c9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:13:44Z","timestamp":1753233224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24019534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1048891X24019534"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e31829f17c9","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Recurrence in Patients Treated With Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e31829f17c9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2013 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}